Format

Send to:

Choose Destination
See comment in PubMed Commons below
Neuroimage Clin. 2015 Mar 24;8:1-31. doi: 10.1016/j.nicl.2015.03.016. eCollection 2015.

Neuroimaging and neuromodulation approaches to study eating behavior and prevent and treat eating disorders and obesity.

Author information

  • 1INRA, UR1341 ADNC, France.
  • 2Radboud University, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands.
  • 3Department of Epileptology, University Hospital Bonn, Germany.
  • 4Department of Life, Health and Environmental Sciences, University of L'Aquila, Italy.
  • 5Massachusetts General Hospital, Harvard Medical School, USA.
  • 6Beth Israel Deaconess Medical Center, Harvard Medical School, USA.
  • 7Old Dominion University, USA.
  • 8INRA, US1395 Ani-Scans, France.
  • 9Oregon Research Institute, USA.

Abstract

Functional, molecular and genetic neuroimaging has highlighted the existence of brain anomalies and neural vulnerability factors related to obesity and eating disorders such as binge eating or anorexia nervosa. In particular, decreased basal metabolism in the prefrontal cortex and striatum as well as dopaminergic alterations have been described in obese subjects, in parallel with increased activation of reward brain areas in response to palatable food cues. Elevated reward region responsivity may trigger food craving and predict future weight gain. This opens the way to prevention studies using functional and molecular neuroimaging to perform early diagnostics and to phenotype subjects at risk by exploring different neurobehavioral dimensions of the food choices and motivation processes. In the first part of this review, advantages and limitations of neuroimaging techniques, such as functional magnetic resonance imaging (fMRI), positron emission tomography (PET), single photon emission computed tomography (SPECT), pharmacogenetic fMRI and functional near-infrared spectroscopy (fNIRS) will be discussed in the context of recent work dealing with eating behavior, with a particular focus on obesity. In the second part of the review, non-invasive strategies to modulate food-related brain processes and functions will be presented. At the leading edge of non-invasive brain-based technologies is real-time fMRI (rtfMRI) neurofeedback, which is a powerful tool to better understand the complexity of human brain-behavior relationships. rtfMRI, alone or when combined with other techniques and tools such as EEG and cognitive therapy, could be used to alter neural plasticity and learned behavior to optimize and/or restore healthy cognition and eating behavior. Other promising non-invasive neuromodulation approaches being explored are repetitive transcranial magnetic stimulation (rTMS) and transcranial direct-current stimulation (tDCS). Converging evidence points at the value of these non-invasive neuromodulation strategies to study basic mechanisms underlying eating behavior and to treat its disorders. Both of these approaches will be compared in light of recent work in this field, while addressing technical and practical questions. The third part of this review will be dedicated to invasive neuromodulation strategies, such as vagus nerve stimulation (VNS) and deep brain stimulation (DBS). In combination with neuroimaging approaches, these techniques are promising experimental tools to unravel the intricate relationships between homeostatic and hedonic brain circuits. Their potential as additional therapeutic tools to combat pharmacorefractory morbid obesity or acute eating disorders will be discussed, in terms of technical challenges, applicability and ethics. In a general discussion, we will put the brain at the core of fundamental research, prevention and therapy in the context of obesity and eating disorders. First, we will discuss the possibility to identify new biological markers of brain functions. Second, we will highlight the potential of neuroimaging and neuromodulation in individualized medicine. Third, we will introduce the ethical questions that are concomitant to the emergence of new neuromodulation therapies.

KEYWORDS:

5-HT, serotonin; ADHD, attention deficit hyperactivity disorder; AN, anorexia nervosa; ANT, anterior nucleus of the thalamus; B N, bulimia nervosa; BAT, brown adipose tissue; BED, binge eating disorder; BMI, body mass index; BOLD, blood oxygenation level dependent; BS, bariatric surgery; Brain; CBF, cerebral blood flow; CCK, cholecystokinin; Cg25, subgenual cingulate cortex; DA, dopamine; DAT, dopamine transporter; DBS, deep brain stimulation; DBT, deep brain therapy; DTI, diffusion tensor imaging; ED, eating disorders; EEG, electroencephalography; Eating disorders; GP, globus pallidus; HD-tDCS, high-definition transcranial direct current stimulation; HFD, high-fat diet; HHb, deoxygenated-hemoglobin; Human; LHA, lateral hypothalamus; MER, microelectrode recording; MRS, magnetic resonance spectroscopy; Nac, nucleus accumbens; Neuroimaging; Neuromodulation; O2Hb, oxygenated-hemoglobin; OCD, obsessive–compulsive disorder; OFC, orbitofrontal cortex; Obesity; PD, Parkinson's disease; PET, positron emission tomography; PFC, prefrontal cortex; PYY, peptide tyrosine tyrosine; SPECT, single photon emission computed tomography; STN, subthalamic nucleus; TMS, transcranial magnetic stimulation; TRD, treatment-resistant depression; VBM, voxel-based morphometry; VN, vagus nerve; VNS, vagus nerve stimulation; VS, ventral striatum; VTA, ventral tegmental area; aCC, anterior cingulate cortex; dTMS, deep transcranial magnetic stimulation; daCC, dorsal anterior cingulate cortex; dlPFC, dorsolateral prefrontal cortex; fMRI, functional magnetic resonance imaging; fNIRS, functional near-infrared spectroscopy; lPFC, lateral prefrontal cortex; pCC, posterior cingulate cortex; rCBF, regional cerebral blood flow; rTMS, repetitive transcranial magnetic stimulation; rtfMRI, real-time functional magnetic resonance imaging; tACS, transcranial alternate current stimulation; tDCS, transcranial direct current stimulation; tRNS, transcranial random noise stimulation; vlPFC, ventrolateral prefrontal cortex; vmH, ventromedial hypothalamus; vmPFC, ventromedial prefrontal cortex

PMID:
26110109
[PubMed - indexed for MEDLINE]
PMCID:
PMC4473270
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk